Drug Trial Radar · NCT07341828
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Feb 2026
Primary completion
Jun 2027
Study completion Feb 2029
Sponsor
- Lead sponsor
- Huashan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai AbelZeta Ltd.
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases refractory to standard therapy
Conditions
- Multiple Sclerosis (MS)
- Neuromyelitis Optica Spectrum Disorders (NMOSD)
- Autoimmune Encephalitis
- Stiff Person Syndrome
Interventions
CD20/BCMA-directed CAR-T cellsBiological
Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of Adverse Events [Safety and Tolerability]Time frame: Throughout the first 3 months follow up period completion
- The subsequent recommended dose of C-CAR168 in patients with central nervous system autoimmune diseases refractory to standard therapyTime frame: Throughout the first 24 months follow up period completion
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.